Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.37 USD | -0.88% | -7.13% | +31.46% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Evolution of the average Target Price on Enanta Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Enanta Pharmaceuticals, Inc.
Oppenheimer | |
HC Wainwright | |
RBC Capital Markets | |
JMP Securities | |
Jefferies & Co. | |
JPMorgan Chase | |
SVB Securities LLC | |
Evercore ISI | |
Baird | |
Roth Capital Partners | |
SVB Leerink | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- ENTA Stock
- Consensus Enanta Pharmaceuticals, Inc.